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ABSTRACT
Von Willebrand disease (VWD) is the most common inherited bleeding disorder
and is due to quantitative and/or qualitative defects of von Willebrand factor (VWF).
Despite the improved knowledge of the disease, detailed data on VWD types requiring
specific treatments have not been reported thus far. To determine the number and types of
VWD requiring therapy with desmopressin (DDAVP) and/or VWF/FVIII concentrates
in Italy, a national registry on VWD (RENAWI) was organized. Only 16 of 48 centers
included VWD in the RENAWI with diagnoses performed locally. Patients with
uncertain results were retested by two expert laboratories using multimeric analysis and
mutations of the VWF gene. A total of 1234 of 1529 (81%) cases satisfied the inclusion
criteria and could be classified as VWD1 (63%), VWD2A (7%), VWD2B (6%), VWD2M
(18%), VWD2N (1%), and VWD3 (5%). VWD types were also confirmed by DNA
analyses and occur in young adults (83%), mainly in women (58%). Mucosal bleedings (32
to 57%) are more frequent than hematomas (13%) or hemarthrosis (6%). Most patients
were exposed to an infusion trial with desmopressin (DDAVP) and found responsive with
the following rates: VWD1 (69%), VWD2A (26%), VWD2M (29%), and VWD2N
(71%). However, DDAVP was not always used to manage bleeding in all responsive
patients and VWF/FVIII concentrates were given instead of or together with DDAVP in
VWD1 (30%), VWD2A (84%), VWD2B (62%), VWD2M (63%), VWD2N (30%), and
VWD3 (91%). Data of the RENAWI showed that correct VWD identification and
classification might be difficult in many Italian centers. Therefore, evidence-based studies
should be organized only in well-characterized patients tested by laboratories that are
expert in the clinical, laboratory, and molecular markers of VWD.
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Von Willebrand disease (VWD) is the most common
inherited bleeding disorder. It is very heterogeneous, and
correct diagnosis and treatment may sometimes be
difficult.1,2 Despite improved knowledge on the man-
agement of VWD as described in several guidelines
prepared by panels of experts on the field,3–7 no detailed
data on the cases requiring specific treatments have been
available thus far. The results of several epidemiological
studies suggested that VWD could be extremely fre-
quent in certain geographic areas.8 The most recent
European and Canadian studies investigating the clinical
and molecular markers for diagnosis and management of
VWD1 could indeed improve the knowledge of the
disease but could not explore the clinical use of specific
therapeutic agents.9,10
A retrospective registry on VWD, called the
Registro nazionale dei pazienti con malattia di Wille-
brand, or the National Registry of Von Willebrand
Disease (RENAWI), was organized in Italy in 2002.
Aims of this registry were to evaluate the natural history
of VWD in Italy in a large cohort of patients (>1000)
and, more specifically, to obtain actual data on number of
VWD types requiring treatment with desmopressin
(DDAVP) and of VWF/factor (F)VIII concentrates.
Since the last largest report on 100 Italian VWD
patients collected from four major Italian Hemophilia
Centers was published in 1977,11 the RENAWI might
describe indeed the natural history of VWD in Italy,
after the first introduction of DDAVP in clinical prac-
tice.12
PATIENTS AND METHODS
Design of the Study
In Italy, the Italian Association of Hemophilia Cen-
ters (AICE) has been organizing a general registry on
hemophilia since late 1980s, but data collected until
late 1990s were mainly devoted to bloodborne infec-
tions observed especially in patients with hemophilia.
Clinical and laboratory parameters on VWD have
been collected since 2002 from 48 Hemophilia Cen-
ters, and general data on VWD have been published
within the registry on Hemophilia and Allied Dis-
orders.13 In the case of VWD patients, the Italian
Ministry of Health supported a specific registry to
collect detailed information about VWD types requir-
ing the use of therapeutic agents such as DDAVP
and/or VWF/FVIII concentrates. Table 1 shows
the different phases of the studies, the number of
participating centers, and patients enrolled in these
two registries.
Data of RENAWI were collected from January
2002 throughout December 2005. Investigators of each
participating center received a computerized program
and were trained to include VWD patients into the
database. Among many other parameters, information
was collected on (1) VWD types with age and sex
distribution, (2) type of bleeding episodes, (3) identifi-
cation of VWD cases responsive to DDAVP, and (4)
number of patients treated with DDAVP only and/or
those with VWF/FVIII concentrates. A total of 16 of 48
centers (33%) could enroll patients into RENAWI.
Patients were defined by specific codes to ensure ano-
nymity. In the case of more patients from the same
family, the family group was also indicated. The first
enrollment was closed on December 2005, but the
participating centers were requested to complete their
data thereafter, and additional information was accepted
by the coordinator until December 2006. During the
first analysis of data, among the 1529 total patients,
>400 cases did not meet the criteria for a correct
Table 1 Italian Centers and Patients Included in
RENAWI versus Those Reported Annually in the
Registry on Hemophilia and Allied Disorders of the AICE
(Update December 2010)
Retrospective Registry (RENAWI: 2002–2006) versus Data of
AICE General Registry (2010)
No. of participating Hemophilia Centers¼16 48
Patients enrolled in the registry in January 2005¼1529 2420
Patients not included in the registry¼295 not applicable
Included by more than one center¼ 35 verified
Did not meet criteria for VWD diagnosis¼ 246 analyses not
tested
Lost at follow-up or died¼ 14 verified
Classification of total VWD included¼ 12342420
VWD1¼779 (63%)1773 (73%)*
VWD2A¼ 87 (7%)208 (9%)
VWD2B¼ 73 (6%)113 (5%)
VWD2M¼219 (18%)164 (6%)*
VWD2N¼10 (1%)40 (2%)
VWD3¼66 (5%) 122 (5%)
*Note that the frequency of VWD1 and VWD2M observed in the
RENAWI is relatively lower and higher (respectively) than that of the
AICE general registry. This is mainly due to the more sensitive
ELISA-VWF:RCo and multimeric analyses used in the RENAWI
allowing a better identification of VWD2M versus previously
diagnosed VWD1 according to fewer tests.
RENAWI, National Registry of von Willebrand Disease; AICE, Italian
Association of Hemophilia Centers; VWD, von Willebrand disease.
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diagnosis of VWD. The Hemophilia Centers were
thus requested to provide additional information to-
gether with plasma samples and DNA sent for addi-
tional laboratory investigations. Despite additional
data, 275 cases remained excluded because of registra-
tion in more than one center (n¼ 35), incomplete or
incorrect diagnosis (n¼ 226), lost at follow-up, or died
(n¼ 14). Eventually, in 2007, 1234 cases were avail-
able for the second analysis, and these could be also
tested for VWF molecular defects during the last
3 years (Table 1).
Ethical Issues, Blood Collection, and Laboratory
Methods
Patients were informed about the anonymous use of
their data as well as the purpose of the study and gave
their informed consent. The study was performed ac-
cording to the Declaration of Helsinki and was approved
by the Ethical Committee of the 16 centers involved in
RENAWI. Venous blood was obtained at each center
during regular screening at the time of diagnosis and at
the time of follow-up visits. Plasma samples were ob-
tained and kept frozen at 408C by the Hemophilia
Centers. Bleeding time (BT) was measured by the
Simplate-II R (Organon Teknica Corp., Durham, NC,
USA), FVIII by one-stage coagulometric assay,
VWF:antigen (Ag) by commercial kits, and homemade
enzyme-linked immunosorbent assay (ELISA) using
polyclonal antibodies against VWF.2,3 VWF:ristocetin
cofactor (RCo) was measured by aggregometry using
formalin-fixed platelets from normal donors; when
plasma VWF:RCo was <15 U/dL, VWD patients
were investigated using the more sensitive ELISA-
VWF:RCo assay.14 Ristocetin-induced platelet aggluti-
nation (RIPA) was performed in platelet-rich plasma by
aggregometry, and changes in light transmission were
inscribed in a potentiometric chart recorder. RIPA
values were expressed in terms of the minimal concen-
tration of ristocetin giving at least a 30% increase in
transmission (the normal range was 0.8 to 1.2 mg/mL
ristocetin).2,3 VWF multimeric pattern was evaluated in
patients’ plasma by low-resolution gel electrophoresis.2,3
For molecular diagnosis, genomic DNA was extracted
from peripheral blood using standard methods. Oligo-
nucleotides used in this study and detailed procedures
are available on request. Polymerase chain reaction was
performed to amplify the whole VWF gene coding
region of the propositus, and sequence analysis was
performed as previously reported.15
Criteria for Diagnosis of Von Willebrand Disease
Types
Unfortunately, at the time of the first design of
RENAWI, the detailed questionnaire later tested in
VWD1 and used to calculate the bleeding score (BS)
was not available;16 therefore, data on BS could not be
reported in the RENAWI. Patients were included in
the RENAWI if they fulfilled all the criteria recom-
mended by the Scientific Standardization Committee,
subcommittee on VWF of the International Society
on Thrombosis & Haemostasis (ISTH), translated
into a diagnostic flowchart in its updated version.3,17
Fig. 1 summarizes the criteria used to classify VWD
patients.
Diagnosis of VWD1 was the most critical and
was based on the VWF:RCo (upper normal limit for
non-O blood group¼ 60 U/dL) and VWF:Ag plasma
levels (upper normal limit for non-O blood group¼ 68
U/dL) and a complete set of multimers in plasma in at
least one member of the same family. According to the
definition of VWD1, characterized by reduced levels
of normal VWF, VWF:RCo and VWF:Ag values
were equally reduced with a VWF:RCo/Ag ratio
>0.6. This value represents the lower limit of the
VWF:RCo/Ag values recently obtained in 1200 nor-
mal individuals used as a control in the European
project Molecular and Clinical Markers on Diagnosis
and Management of type 1 VWD.9 VWD1 patients
showed all three of the criteria (bleeding history,
familial bleeding history, and lower VWF:RCo levels)
recently discussed.5
Participating hematologists were requested to re-
view their diagnosis several times by repeating assays at
their local laboratories; in most cases the final diagnosis
was eventually also confirmed by the coordinating center
by using multimeric analysis and mutations of the VWF
gene. DNA was available in all affected members of
VWD2A, VWD2B, VWD2M, VWD2N and in most
VWD3 (82%) and VWD1 (60%). Most identified
mutations had been previously recorded in the ISTH
VWF database (www.vwf.group.shef.ac.uk; accessed on
December 27, 2010). The typical localization of molec-
ular defects within the entire VWF gene defects is
reported in Fig. 2.
Infusion Trial with DDAVP and Clinical Use
of DDAVP and/or VWF/FVIII Concentrates
Information about the infusion trial with DDAVP and
the clinical use of DDAVP and/or VWF/FVIII con-
centrates were also included in RENAWI. An infusion
trial with DDAVP was recommended in at least one
member of the families with VWD1, VWD2A,
VWD2M, and VWD2N (Fig. 1). To test the biological
response, blood was collected to measure VWF/FVIII
activities before and 1 and 2 hours postinfusion: Patients
were considered responsive to DDAVP according to
recently published criteria.18,19
Only three concentrates containing VWF are
currently licensed in Italy for VWD patients: Alphanate
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(Grifols), Fahndi (Grifols), and Haemate-P (CSL-
Behring). These concentrates contain both VWF and
FVIII and can therefore be defined as VWF/FVIII
concentrates. They were recommended for VWD ther-
apy because they were also assessed for their efficacy and
safety in Italian patients with VWD.20–22
Statistical Analysis
Continuous variables were expressed as mean plus or
minus standard deviation or median and range. Com-
parison between continuous variables was made by the
Student t test, Mann-Whitney U test, or one-way
analysis of variance, where appropriate. All statistical
analysis was performed using the SPSS software package
(version 15.0; SPSS, Chicago, IL, USA).
RESULTS
Demographic, Clinical, and Laboratory Data of
the Von Willebrand Disease Cohort
The data obtained by RENAWI have been collected
using a specific database in only a third of the Italian
centers currently participating in the general registry on
hemophilia and allied bleeding disorders of the AICE.13
Indeed, these 16 of 48 centers in the past 10 years have
been following the majority of the Italian VWD pop-
ulation, that is, 1529 of 2420 cases (63%) (Table 1).
Because only these 1234 patients have been centrally
reevaluated for VWD diagnosis, we decided to describe
the current management of VWD in Italy by using only
data from this well-characterized cohort of patients.
Table 2 summarizes the demographic, clinical, and
Figure 1 Flowchart proposed for the correct diagnosis and classification of different von Willebrand disease (VWD) types,
partially modified from those reported previously.3,17 Once bleeding history of the suspected patients with VWD is collected
and family history of bleeding investigated, a reduced level of von Willebrand factor (VWF) should be measured by using
VWF:ristocetin cofactor (RCo). Level I of diagnosis: VWD3 can be diagnosed in case of undetectable VWF:antigen (Ag). Factor
(F) VIII is always reduced in VWD3 and in VWD2N: It can be reduced or normal in all the other VWD types. VWD2B can be
identified with heightened ristocetin-induced platelet agglutination (RIPA) (<0.8 mg/mL), whereas VWD1, VWD2A, and
VWD2M are characterized by low RIPA (>1.2 mg/mL). A proportionate reduction of both VWF:Ag and VWF:RCo with a
VWF:RCo/Ag ratio >0.6 suggests VWD1. If the VWF:RCo/Ag ratio is<0.6, VWD2A, VWD2B, or VWD2M should be suspected.
VWD2N can be suspected in the case of FVIII:VWF ratio <1. A FVIII:VWF ratio >1 is usually associated with VWD1. Level II of
diagnosis: Multimeric analysis in plasma is necessary to distinguish between VWD2A (lack of the largest and intermediate
multimers) and VWD2M (all the multimers present). VWF propeptide (pp)-to-VWF:Ag is increased in VWD1 with a short half-life
of VWF. Desmopressin (DDAVP) infusion test can identify patients with no biological response or a short biological response to
this drug. VWF:FVIIIB should be performed to confirm VWD2N. Once phenotypic diagnosis is performed, mutations should be
searched for (molecular diagnosis) to confirm VWF defects within the family of VWD patients (Fig. 2). HMW, high molecular
weight; FVIII:C, factor VIII coagulant activity.
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laboratory data of the 1234 cases included in RENAWI.
VWD types could be identified (family n; %) as follows:
VWD1¼ 779 (279; 63), VWD2A¼ 87 (31; 7),
VWD2B¼ 73 (22; 6), VWD2M¼ 219 (67; 18),
VWD2N¼ 10 (5; 1), and VWD3¼ 66 (47; 5). Women
were more frequently diagnosed among all VWD (58%),
especially in milder types (VWD1¼ 60%); they were
equal to men in VWD2A (48%), VWD2N (50%), and
Figure 2 Schematic representation of the von Willebrand factor (VWF) gene located in chromosome 12: The main exons are
indicated with the number of base pairs from 50 to 30 (upper panel). The structure of VWF functional domains: the pre-pro-VWF is
indicated with amino acids numbered from the amino- (aa 1) to carboxy-terminal portions (aa 2813) of VWF. Note the important
CK and D3 domains for formation of VWF dimers and multimers. The native mature subunit of VWF, after the cleaving of the
pre-pro VWF, is described with its functional domains: the VWF binding sites for factor VIII (D’ and D3), Glycoprotein (GP)Ib,
botrocetin, heparin, sulfatide, collagen (A1), collagen (A3), and the RGD sequence for binding to aIIbb3 (intermediate panel).
Distribution of VWF mutations in patients with VWD2: the positions of mutations causing VWD2A, VWD2B, VWD2M, and
VWD2N are indicated with black bars throughout the VWF domains (lower panel).
Table 2 Demographic, Clinical, and Laboratory Data [Median (Range)] of Patients Enrolled in RENAWI
VWD1 VWD2A VWD2B VWD2M VWD2N VWD3 All VWD
No. of cases (%) 779 (63) 87 (7) 73 (6) 219 (18) 10 (1) 66 (5) 1234 (100)
No. of families 279 31 22 67 5 47 451
Gender M/F
(% female)
311/468 (60) 45/42 (48) 29/44 (60) 101/118 (54) 5/5 (50) 32/34 (51) 523/711 (58)
Median age
(yr) (range)
35 (2–87) 34 (3–77) 33 (5–87) 37 (4–96) 20 (4–54) 28 (1–72) 32 (1–96)
Bleeding time (min) 7 (2.5–35) 21 (6–35) 14 (4–35) 10 (3–35) 7 (5–13) 35 (15–35) 15 (2.5–35)
RIPA (mg/mL) 1.30 (1.1–3.5) 2.00 (1.4–3.5) 0.60 (0.3–0.8) 1.60 (1.3–3.5) 1.1 (1.1–1.2) 3.5 (0.3–3.5) 1.50
VWF:RCo (U/dL) 37 (5–56) 6 (2–68) 20 (6–79) 7 (3–50) 37 (26–100) <3 (<3–100) 18
VWF:Ag (U/dL) 40 (5–60) 36 6–140) 48 (16–180) 24 (3–120) 33 (26–98) <1 (<1–180) 28
VWF:RCo/Ag (ratio) 0.92 (0.6–1.6) 0.23 (0.1–0.6) 0.46 (0.1–1) 0.50 (0.1–0.6) 1.0 (0.9–1.3) n.c. (0.1–1.6) 0.61
FVIII:C (U/dL) 52 (2–187) 46 (12–140) 50 (16–140) 35 (2–144) 20 (6–33) 6 (1–22) 35 (1–140)
FVIII/VWF:Ag (ratio) 1.65 (0.8–2) 1. 23 (0.6–2) 1.27 (0.4–2) 1.4 (0.6–2) 0.46 (0.2–0.6) n.c. (0.2–2) 1.28
Bleeding time >30 minutes was calculated as 35; RIPA >3 mg/mL was calculated as 3.5; VWF:RCo <3 and VWF:Ag <1 U/dL was considered
as 1 U/dL to calculate ratios.
RENAWI, National Registry of von Willebrand Disease; VWD, von Willebrand disease; RIPA, ristocetin-induced platelet agglutination; VWF, von
Willebrand factor; RCo, ristocetin cofactor; Ag, antigen; C, coagulant activity; nc, not calculated.
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VWD3 (51%). Patients had a median age of 32 years,
even though VWD2N (median: 20 years) and VWD3
(median: 28 years) cases were diagnosed at younger
ages.
Despite the fact that the BT was not introduced
among the tests recommended for VWD diagnosis,3,17
BT has been used extensively in VWD diagnosis, and it
was prolonged in most cases (15 minutes) with a wide
range from 2.5 to >30 minutes. Values of RIPA were
always >1.1 mg/mL in all VWD except for the 73 cases
with VWD2B, and there were very heterogeneous ac-
cording to the levels of the interactions of reduced or
abnormal VWF with its platelet receptor. According to
the enrollment criteria, the levels of VWF:RCo were
always below the lower limit of normal individuals
with non-O blood group in all VWD except for a
few cases of VWD2A, VWD2B, and VWD2N; in
VWD3, VWF:RCo was undetectable. Differently from
VWF:RCo, the VWF:Ag levels were undetectable or
reduced only in all VWD3 and VWD1, but they were
reduced or normal in all the other VWD types. The ratio
between VWF:RCo and VWF:Ag (VWF:RCo/Ag)
could be always calculated in these VWD cases,
thanks to the use of the most sensitive ELISA-
VWF:RCo performed when VWF:RCo levels were
<15 U/dL.14 Therefore, the classification of VWD1
versus VWD2M based on VWF:RCo/Ag >0.6 or <0.6
could be obtained also in patients with very low levels of
VWF:Ag.
FVIII levels were always reduced in VWD3
because of undetectable levels of VWF:Ag and in the
case of VWD2N because of the defective VWF binding
to FVIII (VWF:FVIIIB). As the last parameter used to
characterize our VWD cohort, we calculated the ratios
between FVIII and VWF:Ag and found that FVIII-to-
VWF:Ag was always >1.2 in all VWD except for
VWD2N.
Patients with Different Von Willebrand Disease
Types and Bleeding Symptoms
Table 3 shows the number (percentage) of patients with
VWD types who had at least one episode among the 11
bleeding symptoms considered at the time of their
inclusion in RENAWI. Mucosal bleedings such as
epistaxis (57%), menorrhagia (53%), bleeding from mi-
nor wounds (38%), and gum bleeding (32%) were more
frequently observed than hematomas (13%) and joint
bleeding (6%). The percentages of symptoms are much
higher in the most severe VWD types such as VWD3,
VWD2A, and VWD2B, as shown by the very dramatic
cerebral bleeding (VWD3) and gastrointestinal bleeding
(VWD2A, VWD2B, and VWD3). However, the per-
centages of patients who experienced some mucosal
bleedings such as epistaxis, menorrhagia, and gum
bleeding do not differ significantly among VWD types.
Conversely, hematomas and joint bleedings were more
frequently observed in VWD2N and VWD3 patients
characterized by relatively low levels of FVIII. Note that
there were patients who did not show any symptoms at
the time of the inclusion in RENAWI despite the lower
levels of VWF activities measured in their plasma.
Molecular Diagnosis of Patients with Von
Willebrand Disease
Molecular diagnosis was performed by two Italian labo-
ratories on DNA available in at least one affected
member of the 328 of 451 families (73%) with VWD.
Although all families with VWD2A, VWD2B,
VWD2M, and VWD2N could be tested, DNA samples
from only 168 of 279 VWD1 families (60%) and 54 of
66 VWD3 families (82%) were available for the analyses.
Table 4 summarizes the most frequent molecular
defects found in VWD patients. As far as VWD1, a
relatively large cohort of patients (n¼ 108.9%) carried
Table 3 Number of Patients (%) Who Showed One of the Different Bleeding Symptoms
VWD1 VWD2A VWD2B VWD2M VWD2N VWD3 All VWD
No. of cases (%) 779 (63) 87 (7) 73 (6) 219 (18) 10 (1) 66 (5) 1234 (100)
Epistaxis 412 (53) 61 (70) 49 (67) 123 (56) 4 (40) 51 (77) 699 (57)
Menorrhagia* 374 (48) 25 (40) 26 (59) 105 (58) 2 (40) 22 (65) 654 (53)
Postdental extraction 327 (42) 37 (43) 27 (37) 92 (42) 3 (30) 27 (41) 456 (37)
Bleeding from minor wounds 273 (35) 31 (36) 37 (51) 81 (37) 3 (30) 36 (55) 469 (38)
Gum bleeding 210 (27) 38 (44) 31 (42) 70 (32) 0 (–) 38 (58) 394 (32)
Postsurgical bleeding 280 (36) 42 (48) 35 (48) 98 (45) 2 (20) 30 (45) 494 (40)
Gastrointestinal bleeding 31 (4) 15 (17) 7 (10) 18 (8) 0 (–) 13 (20) 87 (7)
Hematomas 93 (12) 12 (14) 12 (16) 13 (6) 4 (40) 31 (47) 161 (13)
Joint bleeding 15 (2) 7 (8) 12 (16) 13 (6) 1 (10) 27 (41) 78 (6)
Hematuria 16 (2) 5 (6) 3 (4) 7 (3) 1 (10) 8 (12) 40 (3)
Cerebral bleeding 5 (0.6) 2 (2) 0 (–) 1 (0.6) 0 (–) 6 (9) 14 (1)
*Women only.
Underlined values indicate similar percentages among the noted VWF types.
VWD, Von Willebrand disease.
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the mutation R1205H with or without M740I typically
observed in VWD1 ‘‘Vicenza.’’ Among other frequent
gene defects observed in the Italian VWD1, the follow-
ing molecular abnormalities could be identified: small
deletion or insertions (D1277/E78delinsE), missense
(C1130F/R, A1716P, V1822G, R2318H, C2362F,
S2469P), or nonsense (Q1475X, R1779X) mutations.
In the DNA from the 54 of 66 VWD3 patients, the
molecular abnormalities were heterogeneous (pt-n):
large deletion (7); small deletions and insertions (18);
nonsense (9); and splice site (8) and missense (12)
mutations. Note that the seven VWD3 patients charac-
terized by large gene deletions had at least one episode
of life-threatening anaphylactic reaction in their
lifetime.
DDAVP Trial and Clinical Use of DDAVP and/or
VWF/FVIII Concentrates
Information was also collected about previous exposures
to DDAVP trial and to DDAVP or VWF/FVIII con-
centrates used to treat bleeding episodes. Data are
summarized in Table 5. A DDAVP trial was performed
in at least one affected member of VWD family as
follows: VWD1 (74%), VWD2A (70%), VWD2M
(72%), and VWD2N (70%). No patient with VWD3
and only a minority of VWD2B (41%) cases were
currently exposed to this trial. However, even though
DDAVP trial showed a good rate of biological re-
sponses: VWD1, 69%; VWD2A, 26%; VWD2M,
33%; and VWD2N, 71%, not all these patients were
treated with DDAVP to manage or prevent bleeding.
For comparison, the percentages of patients with VWD1
(30%), VWD2A (84%), VWD2B (62%), VWD2M
(63%), VWD2N (30%), and VWD3 (91%) who were
exposed to VWF/FVIII concentrates with or without
DDAVP are shown in Table 5. As far as the amount and
frequency of the clinical use of these two main thera-
peutic agents, we could identify the number of VWD
patients who were given DDAVP (more than five doses
per year) and VWF/FVIII concentrates (>50,000
VWF:RCo IU/year). The frequency and the dosage of
DDAVP as well as of VWF/FVIII concentrates have
been reported to be very heterogeneous among the
VWD types (Table 5). The percentages of VWD who
received relatively large amount of DDAVP and or
VWF/FVIII concentrates are relatively low, 11% and
19%, respectively, of the total cohort of patients. Within
this group of VWD treated more frequently, 11 patients
were under secondary long-term prophylaxis as reported
elsewhere.23 However, there were VWD patients who
had never been exposed to bleeding and therefore also
never been exposed to DDAVP and/or VWF/FVIII
concentrates.
DISCUSSION
The data of this retrospective registry on Italian patients
with inherited VWD (RENAWI) have been collected
and analyzed for >8 years. Even though the first sets of
Table 4 List of the Most Frequent Mutations in Italian Von Willebrand Disease According to Von Willebrand Factor
Domains
Localization of VWF Defects VWD Types VWF Mutations Associated with Specific Types
D’–D3 domains VWD2N R816W/Q; R854Q/W; R924Q; C1060R
D3 domain VWD1 Vicenza R1205H (M740I)
VWD1 C1130F/R
VWD2A C1143Y; C1173R
(formerly IIE)
A1 domain VWD2B P1266L/Q; H1268D; R1306Q/L/W;
(formerly IIB) R1308C/P; I1309V; V1316M
P1337L; R1341Q/W
VWD2M R1315C/L; Y1321C/W; R1374C/H
A2 domain VWD2A S1506L; S1543F; R1597W; V1607D
(formerly IIA) G1629R; G1631D; V1665E
VWD1 Y1584C
A3 domain VWD1 A1716P; V1822G
CK and other domains VWD1 R2313H; C2362F; S2469P
VWD2A Q2520P
(formerly IID)
*Note that in the case of patients with VWD3 and VWD1, additional molecular defects have been identified but could not be reported in this
article because most of them are novel and currently under evaluation in expression studies in collaboration with other colleagues. The
frequency of these mutations is described in the text.
VWF, von Willebrand factor; VWD, von Willebrand disease.
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results could be collected at the end of 2002, it took
almost 4 years to complete the revision of phenotypic
data of the first cohort of 1529 patients included as ‘‘bona
fide’’ VWD according to local tests. Two laboratories
expert on VWF assays retested those patients (n¼ 400)
who showed borderline VWF levels in plasma using not
only more standardized assays for VWF:RCo and
VWF:Ag but also multimeric analyses and
VWF:FVIIIB assays as recommended.3,17 After this
reevaluation, 295 of 1529 (19%) still did not meet
criteria for VWD diagnosis and therefore were excluded
from any further analyses. These findings confirmed that
appropriate laboratory tests useful to make VWD diag-
nosis are not available in many Italian centers. This is
especially true for molecular diagnosis because the 1234
patients could be characterized by gene defects during
the last 3 years only in a few laboratories. Eventually,
after such an extensive revision of phenotype and gen-
otype, we could identify one of the largest cohorts of
well-characterized patients useful to describe the current
management of VWD in Italy.
In all the reviews about VWD published for the
past 25 years, VWD1 has been considered the most
frequent VWD (>70%).1–5 A frequency of >70% in
VWD1 was also reported previously by the two Italian
publications of the AICE 2,3 before the current analyses
of RENAWI. The relatively lower percentage of VWD1
(63%) in RENAWI is believed to be more correct
because it is balanced by the relative larger number of
VWD2M patients (18%) who could be diagnosed ac-
cording to the more appropriate criteria used in the
current analyses. Indeed, the VWF:RCo/Ag ratio using
the most sensitive ELISA-VWF:RCo was critical in the
differential diagnosis between VWD1 and VWD2M in
all patients including also those VWD with VWF:RCo
levels <15 U/dL.14 Such a relatively lower percentage of
VWD1 because of misdiagnosed VWD2M or VWD2A
has been also shown previously by other authors. 24,25
Some authors could report lower percentages of VWD1
using the VWF:RCo/Ag ratios and genotypes; 24 others
could identify higher percentages of VWD2A or
VWD2M by using sensitive multimeric analyses and
genotypes.25 In agreement with these reports, we could
identify all the VWD types of RENAWI more appro-
priately using VWF:RCo/Ag ratios, multimeric analy-
ses, and genotypes.
Several authors proposed the use of collagen-
binding activity of VWF (VWF:CB) with VWF:CB-
to-Ag ratios in the differential diagnosis between
VWD1 and VWD2A or VWD2M.26–28 This approach
can be useful sometimes, but unfortunately, VWF:CB
was available in Italy only in a few centers, and therefore
only a minority of cases could be tested with this assay
(data not shown). VWD2B was identified mainly by
RIPA, independently from the VWF:RCo/Ag ratio and
multimeric analyses, as discussed recently;29 differential
VWD2A or VWD2M diagnoses always required multi-
meric analyses in the presence of VWF:RCo/Ag <0.6.
All VWD2N showed low levels of FVIII with a
FVIII/VWF-to-Ag ratio <1, but these were confirmed
Table 5 Patients in RENAWI Exposed to Desmopressin (DDAVP) Infusion Trial and to One or More Therapeutic
Agents after Evaluation of DDAVP Biological Response
VWD1 VWD2A VWD2B VWD2M VWD2N VWD3 All VWD
No. of cases (%) 779 (63) 87 (7) 73 (6) 219 (26) 10 (1) 66 (5) 1234 (100)
DDAVP trial and
biological responses:
DDAVP trial (%) 576 (74) 61 (70) 30 (41) 158 (72) 7 (70) 5 (7) 837 (68)
Biological response
to DDAVP*
397/576 (69%) 15/61 (26%) 6/30 (20%) 52/158 (33%) 5/7 (71%) 0/5 (0%) 467/837 (56%)
Clinical use of DDAVP
and/or VWF/FVIII
concentrates during
the previous 12 mo:
DDAVP 270/779 14/87 10/73 64/219 4/10 0/66 376/1234
(35%) (16%) (14%) (29%) (40%) (0%) (30%)
Patients with
>5 doses/yr
108/779 (14%) 5/87 (6%) 2/73 (3%) 15/219 (7%) 2/10 (20%) 0/66 (0%) 132/1234 (11%)
VWF/FVIII
concentrates
237/779 (30%) 73/87 (84%) 45/73 (62%) 138/219 (63%) 3/10 (30%) 60/66 (91%) 463/1234 (36%)
Patients with
>50,000 UI/yr
(VWF:RCo)
86/779 (11%) 31/87 (36%) 23/73 (31%) 56/219 (26%) 1/10 (10%) 37/66 (56%) 234/1234 (19%)
*The definition of biological response is described within the text.
RENAWI, National Registry of von Willebrand Disease; VWF, von Willebrand factor; F, factor.
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by the specific VWF:FVIIIB assay. The frequency of
VWD2N patients in the RENAWI is apparently lower
than that reported by the current literature. 1,4–6 How-
ever, we could have missed additional patients with
VWD2N because the specific VWF:FVIIIB assay was
not performed in all VWD. Patients with VWD3
showed undetectable levels of VWF:Ag and very
reduced levels of FVIII. Seven patients from three
different families developed anti-VWF inhibitors with
life-threatening reactions in their lifetime.30–32 The
assay for VWF propeptide was available in only two
centers and was used only in a few patients, especially in
those with VWD1 ‘‘Vicenza’’ (data not shown). Despite
the fact that BT was not recommended by the AICE,
this assay is still in use in most Italian centers; the PFA-
100 is currently used in only a few centers (data not
shown).
The number of patients who showed different
bleeding symptoms was analyzed according to the most
recent classification of VWD types within RENAWI,
and therefore the percentages are different from those
shown in our previous reports.2,3 Nevertheless, we con-
firm that mucosal bleedings such as epistaxis, menor-
rhagia, bleeding from minor wounds, gum bleeding)
were more frequently observed than hematomas (13%)
and joint bleeding (6%). Unfortunately, we could report
only the type of symptoms without the semiquantitative
evaluation of bleeding severity because we could not
apply at the time of the study the questionnaire used to
calculate the BS.16 This semiquantitative evaluation of
bleeding symptoms has so far been used for the pro-
spective study organized within the same cohort of
patients, but only on 797 of 1234 patients (65%) (data
not shown).
Molecular diagnosis was performed in most of the
affected members with VWD types, and the results
obtained were useful to determine family groups with
specific genotype. For instance, we could find a very high
frequency of the mutation R1205H with or without
M740I typically observed in VWD1 ‘‘Vicenza’’ in 108
of 1234 patients (9%).33,34 Among other mutations
found in this cohort of patients, the most frequently
(more than five families) observed are the following:
C1130F/R, R1306Q/L/W, R1308C/P, R1315C/L,
R1374C/H, R1597W, and Y1584C. In the case of
VWD3 patients, the molecular abnormalities were het-
erogeneous: It is important to identify that all seven
patients with a large deletion of the VWF gene showed
the presence of anti-VWF inhibitors and showed life-
threatening anaphylactic reactions 31,32. However, larger
prospective studies should be organized to determine
predictors of bleeding and of anti-VWF inhibitors in
VWD3.35
As far as the treatment of Italian VWD, the
results of RENAWI showed that DDAVP was regularly
assessed as part of the diagnostic workup in most VWD
patients. All the hematologists were aware of the stand-
ardized protocol and could evaluate correctly the bio-
logical response after a DDAVP trial according to
previous recommendations.18,19 Nevertheless, even
though a DDAVP trial showed a relatively high rate
of biological response, not all these patients were treated
with DDAVP to manage or prevent bleeding. This
apparent contradiction is currently under evaluation in
a multicenter prospective clinical trial on the use of
DDAVP in >200 VWD patients.36
Compared with patients with hemophilia, VWD
patients are certainly less exposed to severe bleeding, and
therefore it is not surprising that only a small percentage
of VWD cases usually are treated with VWF/FVIII
concentrates following spontaneous and/or trauma-in-
duced bleeds. Nevertheless, even thought there are
VWD patients who bleed only rarely and therefore use
DDAVP or VWF/FVIII concentrates usually only to
prevent bleeding during surgery, there is a group of
VWD cases in RENAWI who are regularly treated.
These patient not only receive large amounts of
VWF:FVIII concentrates, but also a few of them are
currently under secondary long-term prophylaxis be-
cause of recurrent bleedings at the same sites: gastro-
intestinal bleeding (VWD1, VWD2A, VWD2M) and
hemarthrosis (VWD3).23 Therefore data from RE-
NAWI were also useful to make an estimate on the
current use of DDAVP and VWF/FVIII concentrates
per year in Italian VWD as requested by the Italian
Ministry of Health. The predictors of bleeds in patients
with VWD and the need for DDAVP and VWF/FVIII
concentrates are currently under evaluation in another
prospective study.35,36 Even though it was not a specific
aim of RENAWI, the Italian patients with VWD
previously exposed to plasma-derived VWF/FVIII con-
centrates have been also evaluated for their incidence of
bloodborne infections. Thanks to the use of DDAVP
since 1977 and of a pasteurized VWF/FVIII concentrate
since 1984, the incidence of hepatitis C virus infection is
relatively low.37
In conclusion, the information gathered in RE-
NAWI from one of the largest cohorts of well-charac-
terized VWD patients has been extremely useful to
better understand the current management of Italian
patients and can be compared with data obtained from
other countries. Despite many attempts to improve the
diagnostic workup of VWD, appropriate phenotypic and
genotypic tests are not available in most hemophilia
centers: Only a few laboratories could perform the
correct identification and classification of VWD type.
This suggests that evidence-based studies should be
performed only in well-characterized patients tested by
laboratories expert in the clinical, laboratory, and mo-
lecular markers of VWD: These studies should aim at
evaluating the predictors of bleeding according to these
markers. The clinical use of DDAVP >30 years after its
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introduction in Italy was certainly less frequent than
expected from the data of biological response. Only
the results of another large prospective study can
provide the reasons of these discrepant findings. Last
but not least, the VWF/FVIII concentrates used in
Italy have been effective and safe in most patients with
VWD who have been treated with them to stop
bleeding, to prevent bleeding during major/minor
surgeries, and also in a few cases in secondary long-
term prophylaxis.
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